This document provides information about rhinitis (inflammation of the nose). It defines rhinitis and describes the main types including allergic, infectious, non-allergic non-infectious, and chronic rhinosinusitis. It discusses the pathophysiology, diagnosis, and management of allergic rhinitis in particular. Allergic rhinitis is mediated by IgE and causes nasal inflammation and hyperreactivity. Diagnosis involves assessing symptoms, examining the nose, and performing allergy tests. Management follows guidelines and includes environmental control, pharmacotherapy with oral or intranasal antihistamines, leukotriene receptor antagonists, nasal steroids, and decongestants.
Allergic rhinitis is a very much prevalent condition in the community. This presentation hopes to spread a ray of hope in treating allergic and intrinsic rhinitis.
Allergic rhinitis is a very common disorder that affects people of all ages. It is frequently ignored, under diagnosed, misdiagnosed, and mistreated, which not only is detrimental to health but also has societal costs. Although allergic rhinitis is not a serious illness, it is clinically relevant because it underlies many complications, is a major risk factor for poor asthma control, and affects quality of life and productivity at work or school. Hidden direct costs include the treatment of co-morbid asthma, chronic sinusitis, otitis media, upper respiratory infection, and nasal polyp. Nasal congestion, the most prominent symptom in AR, is associated with sleep-disordered breathing, a condition that can have a profound effect on mental health, including increased psychiatric disorders, depression, anxiety, and alcohol abuse. Furthermore, sleep-disordered breathing in childhood and adolescence is associated with increased disorders of learning performance, behavior, and attention. Management of allergic rhinitis is best when directed by guidelines. At this juncture Homoeopathic system of medicine offers a safe and effective solution of the illness if followed under the guidance of expertise. This article provides an overview of the patho-physiology, diagnosis, and appropriate homoeopathic management of this disorder.
Dr. Smita Brahmachari
M.O., Dept. of AYUSH, Govt. of NCT Delhi.
Airway diseases presenting with behavior of Reaction to any trigger have been in increase. We intend to visit available resources for better understanding of RAD - in Children and adults
Allergic rhinitis is a very much prevalent condition in the community. This presentation hopes to spread a ray of hope in treating allergic and intrinsic rhinitis.
Allergic rhinitis is a very common disorder that affects people of all ages. It is frequently ignored, under diagnosed, misdiagnosed, and mistreated, which not only is detrimental to health but also has societal costs. Although allergic rhinitis is not a serious illness, it is clinically relevant because it underlies many complications, is a major risk factor for poor asthma control, and affects quality of life and productivity at work or school. Hidden direct costs include the treatment of co-morbid asthma, chronic sinusitis, otitis media, upper respiratory infection, and nasal polyp. Nasal congestion, the most prominent symptom in AR, is associated with sleep-disordered breathing, a condition that can have a profound effect on mental health, including increased psychiatric disorders, depression, anxiety, and alcohol abuse. Furthermore, sleep-disordered breathing in childhood and adolescence is associated with increased disorders of learning performance, behavior, and attention. Management of allergic rhinitis is best when directed by guidelines. At this juncture Homoeopathic system of medicine offers a safe and effective solution of the illness if followed under the guidance of expertise. This article provides an overview of the patho-physiology, diagnosis, and appropriate homoeopathic management of this disorder.
Dr. Smita Brahmachari
M.O., Dept. of AYUSH, Govt. of NCT Delhi.
Airway diseases presenting with behavior of Reaction to any trigger have been in increase. We intend to visit available resources for better understanding of RAD - in Children and adults
Similar to 000 84 AWESOME SLIDES EDIT TO FROM Investigating and managing upper airway disorders.pdf (20)
004 4 slides ANATOMY AND PHYSIOLOGY OF PARANASAL SINUSES.pptxDeniseMathre1
The Structure and Function of the anatomy and physiology of the 5th cranial nerve - three pairs of nerve the tri geminus nerve also called the tregeminal nerve. It supplies three arteries on left and on right
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
2. • Rhinitis: Symptomatic disorder of the nose
characterized by itching, nasal discharge,
sneezing and nasal airway obstruction
• Allergic rhinitis: Induction of rhinitis
symptoms after allergen exposure by an
IgE-mediated immune reaction;
accompanied by inflammation of the nasal
mucosa and nasal airway hyperreactivity.
3. Rhinitis Phenotypes
most common forms
• Allergic
• Infectious: Viral (acute), bacterial, fungal
• Non-Allergic, Non-Infectious, Rhinitis
• Non-Allergic Rhinitis with Eosinophilia Syndrome (NARES)
• Chronic Rhinosinusitis with or without Polyps: Hypertrophic,
inflammatory disorder that can affect allergic or non-allergic individuals
4. Non-allergic rhinitis
• Has a multifactorial etiology.
• Is a risk factor for the development of asthma.
• If eosinophilic, usually responds to treatment
with corticosteroids.
• May be a presenting complaint for systemic
disorders such as Wegener’s granulomatosis,
Churg–Strauss and sarcoidoisis.
6. • Occupational: May be allergic or non-allergic
• Drug-induced: Aspirin, some vasodilators
• Hormonal: Pregnancy, menstruation, hormonal contraceptives,
thyroid disorders
• Food-induced (gustatory)
• Cold air-induced (skier’s nose)
• Atrophic (rhinitis of the elderly)
Rhinitis Phenotypes
less common forms
9. Cameron et al J Immunol 2003;171:3816
In situ hybridization for Iε mRNA - tissue obtained from subjects with alleric rhinitis
Iε RNA+ cells
(germline transcript)
Not exposed to
ragweed
Exposed to
ragweed
IgE can be produced in the nasal mucosa
10. Local Allergic Reaction
(nasal challenges with allergen in non-allergic rhinitics)
Carney et al. Clin Exp Allergy 2002;32:1436
Resistance
(most obstructed
nostril)
Individual data
Individual data
N=21
N=21
0
0
pre
pre-
-challenge
challenge
post
post-
-challenge
challenge
10
10
8
8
6
6
4
4
2
2
All these subjects had
no response to a control
challenge with diluent
11. Allergic Rhinitis: Impact
• High prevalence
• Impaired quality of life
• Work and school absence
• Impaired learning
• Impaired sleeping
• Associated asthma, sinusitis, otitis
12. Adapted from Meltzer EO et al. J Allergy Clin Immunol. 1997;99:S815
Short Form Health Survey (SF-36)
Profiles of Patients with Allergic Rhinitis
*
*
*
*
*
*
50
55
60
65
70
75
80
85
90
Physical
Functioning
Role–
Physical
Bodily
Pain
General
Health
Vitality Social
Functioning
Role–
Emotional
Mental
Health
Change in
Health
allergic rhinitis (n=312)
controls (n=139)
†
Declining
health
status
Domains
scale: 0 to 100
14. Berrettini et al., Allergy. 1999;54:242-8.
Presence of Sinus Disease Based on CT Findings in
Patients with Allergic Rhinitis and Controls
67.5%
33.4%
0
5
10
15
20
25
30
35
40
Number of subjects
Allergic rhinitis Controls
Total
With positive sinus CT
p=0.017
15. Allergic Rhinitis as a Risk Factor for Chronic Sinusitis
Ear Nose Throat-related flight disqualifying events that developed
over a 5-year period in Naval Flight Personnel with only allergic
rhinitis (N=465) versus controls (N=12,628)
Walker C. et al. Aviat Space Environ Med. 1998; 69:952
Relative Risk 95% CI
Chonic Sinusitis 4.5 (1.7-11.6)
Alternobaric
Disease
1.6 (0.4-6.6)
Polyposis 1.2 (0.2-8.7)
Conductive Hearing
Loss
0.9 (0.1-6.6)
Requirement for
ENT Surgery
3.4 (0.4-27.1)
16. Allergic rhinitis: The basis of co-morbidity with otitis
media with effusion
Allergic inflammation
and edema obstruct
the eustachian tube
Allergic nasopharyngeal
obstruction and secretions
facilitate microbial middle ear
inflammation
Middle ear functions
as an allergic target
organ
Adapted from Sobotta, Atlas der Anatomie des Menschen. Bd. 1, 21; 2000.
17. ALLERGIC RHINITIS AND ITS IMPACT ON
ASTHMA
ARIA
JACI 2001:56: 813-824
Allergy 2008: 63 (Suppl. 86): 8–160
18. Perennial Rhinitis:
an Independent Risk Factor for Asthma
(European Community Respiratory Health Survey)
adapted from Leynaert B et al. J Allergy Clin Immunol 1999; 104:301
asthma (%)
Atopic Non atopic
no rhinitis, N=5198
rhinitis, N=1412
OR=11
OR=17
0
5
10
15
20
25
19. In Patients with Rhinitis:
– Routinely query for symptoms suggestive of asthma
– Perform chest examination
– Consider lung function testing
– Consider tests for bronchial hyperresponsiveness in
selected cases
20. Intermittent
Symptoms
• < 4 days / week
• or < 4 weeks
Persistent
Symptoms
• > 4 days / week
• or > 4 weeks
Mild
• Sleep: normal
• Daily activities (incl. sports):
normal
• Work-school activities:
normal
• Severe symptoms: no
Moderate- severe
• Sleep: disturbed
• Daily activities: Restricted
• Work and school activities:
disrupted
• Severe symptoms: yes
Allergic Rhinitis Classification
22. Globally Important Sources of Allergens
• House dust mites
• Grass, tree and
weed pollen
• Pets
• Cockroaches
• Molds
23. Diagnosis of Allergic Rhinitis:
• Detailed personal and family allergic
history
• Intranasal examination – anterior
rhinoscopy
• Symptoms of other allergic diseases
• Allergy skin tests and/or
• In vitro specific IgE tests
27. Immunoassay
• Not influenced by
medication
• Not influenced by skin
disease
• Does not require
expertise
• Quality control possible
• Expensive
Skin test
• Higher sensitivity
• Immediate results
• Requires expertise
• Cheaper
Immunoassay vs Skin Test for Diagnosis of Allergy
29. Peak nasal inspiratory flow
• Determines nasal airway patency using a nasal inspiratory
flow meter.
•
• The results are reproducible and correlate with rhinoscopic
evidence of rhinitis but not with symptom scores
• Most useful for comparing changes in airway patency within
the same subject
Allergy 2005; 60:795–800
30. Acoustic rhinometry.
• Measures changes in mucosal congestion using reflected
sound.
• Sound in the nasal cavity is reflected by changes in acoustic
impedance caused by changes in cavity dimensions.
• The change in acoustic impedance between the incident wave
and reflected sound waves is proportional to the cross-
sectional area.
• The method requires standardization and considerable
experience to interpret and obtain reproducible results.
Rhinology 2000; 16 (Suppl.):3–17.
31. Rhinomanometry
• Estimation of nasal resistance from pressure–flow relationships.
• Considered as an accurate measure of nasal airway patency.
• Anterior RM: Pressure sensor is placed at the tip of each nostril and
resistance is
• measured in each nostril separately.
• Posterior RM: Pressure sensor is placed in the back of the nasal
cavity and total nasal airway resistance is determined.
• Expensive equipment
• Requires considerable experience in interpretation
32. Endothelial
cell activation
Leukocyte
infiltration and activation
(lymphocytes, eosinophils,
basophils)
IMMEDIATE (early)
RESPONSE
LATE-PHASE
RESPONSES
preformed &
newly formed
mediators/cytokines
mast cell
Sneezing
Pruritus
Rhinorrhea
Nasal obstruction
Ocular symptoms
Nasal obstruction
Rhinorrhea
Nasal
hyperresponsiveness
To allergens
(priming)
To irritants and to
atmospheric
changes
IgE
allergen
dendritic cell
T-lymphocyte
cytokines
chemokines
allergen
B-lymphocyte
IgE
IL-4
IL-13
The Nasal Allergic Response
37. Stepwise Management of Allergic Rhinitis
Environmental control
Intermittent symptoms Persistent symptoms
Mild
• Oral H1-blocker or
• Intranasal H1
blocker
• and/or decongestant
• or LTRA
Moderate Mild
Severe
• Oral H1 blocker or
• Intranasal H1 blocker
• and/or decongestant or
• Intranasal CS
• or anti-leukotriene
Re-evaluate patient with
persistent symptoms in 2-4
weeks
Modified from ARIA workshop, 2001
Moderate
Severe
• Intranasal CS ±
• H1 blocker or
• anti-leukotriene
Re-evaluate in 2-4 weeks
Responsive:
Step down
Continue treatment
for > 1 month
Unresponsive:
Re-evaluate
compliance
diagnosis
infections
Add or
increase CS
Rhinorrhea:
add ipratropium
Congestion:
add decongestant
± short course of
oral CS
Unresponsive:
Immunotherapy
Consider surgical approaches (?)
Responsive:
Continue treatment
for 1 month
Unresponsive:
Step-up
38. Environmental Control
• House dust mites
• Pets
• Cockroaches
• Molds
• Pollen
1. Allergens
2. Pollutants and Irritants
39. Allergen Avoidance
• Pets
• Remove pets from bedrooms and, even better, from the entire home
• Vacuum carpets, mattresses and upholstery regularly
• Wash pets regularly (±)
• Molds
• Ensure dry indoor conditions
• Use ammonia to remove mold from bathrooms and other wet spaces
• Cockroaches
• Eradicate cockroaches with appropriate gel-type, non-volatile, insecticides
• Eliminate dampness, cracks in floors, ceilings, cover food; wash surfaces, fabrics to remove
allergen
• Pollen
• Remain indoors with windows closed at peak pollen times
• Wear sunglasses
• Use air-conditioning, where possible
• Install car pollen filter
40. House dust mite allergen avoidance
– Provide adequate ventilation to decrease humidity
– Wash bedding regularly at 60°
C
– Encase pillow, mattress and quilt in allergen impermeable covers
– Use vacuum cleaner with HEPA filter
– Dispose of feather bedding
– Remove carpets
– Remove curtains, pets and stuffed toys from bedroom
41. Environmental Control
• The most logical strategy for disease that relates to the
indoor environment
• Effectiveness requires comprehensive and multifaceted
measures
• More studies are needed to also address the role of
indoor pollutants (e.g. NO2, PMs, tobacco smoke,
endotoxin)
46. Simons, F. E. R. N Engl J Med 2004;351:2203
Simplified Two-State Model of the Histamine H1-Receptor
47. Sneezing Rhinorrhea Pruritus Nose Pruritus Eyes Congestion
*
*
*
*
*
*
*
*
*
*
*
*
*
1.0
0.8
0.6
0.4
0.2
0
1 wk
4 wk
6 mo 1 wk
4 wk
6 mo 1 wk
4 wk
6 mo 1 wk
4 wk
6 mo 1 wk
4 wk
6 mo
Bachert C et al. J Allergy Clin Immunol 2004:114:838
mean
Individual
symptom
score
improvement
Levocetirizine, 5 mg, N = 276
Placebo, N = 271
Efficacy of an Antihistamine over 6 Months in
Persistent Allergic Rhinitis
Baseline total symptom score: 8.95
* P<0.05
48. Placebo
N =201
Fexofenadine 120 mg
N =211
Fexofenadine 180 mg
N =202
Cetirizine 10 mg
N =207
*
* *
Change from
baseline in
total symptom
score
(AM, instantaneous,
trough)
0
-0.5
-1.0
-1.5
-2.0
-2.5
-3.0
Newer Antihistamines are Equally Effective
in the Treatment of Allergic Rhinitis
Howarth P et al. J Allergy Clin Immunol 1999;104:927
*: <0.05 compared to placebo
50. • First line treatment for mild allergic rhinitis
• Effective for
– Rhinorrhea
– Nasal pruritus
– Sneezing
• Less effective for
– Nasal blockage
• Possible additional anti-allergic and anti-inflammatory effect
• In-vitro effect > in-vivo effect
• Minimal or no sedative effects
• Once daily administration
• Rapid onset and 24 hour duration of action
Newer Generation Oral Antihistamines
55. Mechanism of Action of Ipratropium Bromide
brain
RHINORRHEA
sensory
nerves
epithelium
submucosal glands
vidian nerve
Acetylcholine
on
muscarinic
receptors
X
X
direct effect of mediators:
not cholinergic
indirect effect:
cholinergic
56. Adapted from Meltzer E at al. J Allergy Clin Immunol 1992;90:242
Efficacy of Ipratropium Bromide Against
Rhinorrhea in Allergic Rhinitis with Perennial Symptoms
6.0 3.0
5.0
4.0
3.0
2.0
1.0
0
2.5
2.0
1.5
1.0
0.5
0
*
*
*
*
* *
*
Ipratropium, 42 µg/nostril three times daily, N=42
Ipratropium, 21 µg/nostril three times daily, N=39
Placebo, N=42
Mean Severity
Score
(scale: 0-5)
Mean Duration
(hours/day)
Baseline Wk 4
Wk 1 Wk 2 Wk 3 Baseline Wk 4
Wk 1 Wk 2 Wk 3
* p<0.05 against Placebo
57. Anticholinergic Treatment: Ipratropium Bromide
• Nasal glands are activated by muscarinic, cholinergic receptors
• Ipratropium bromide is a nonselective muscarinic receptor antagonist
• Ipratropium bromide applied intranasally blocks rhinorrhea induced by
cholinergic stimulation
• Ipratropium bromide has negligent systemic anticholinergic activity
• Topical adverse effects: excessive dryness, epistaxis
60. Daytime Nasal Symptoms Score
(0-3 point scale)
-0.6
-0.4
-0.2
0
Adapted from Nayak, et al. Ann Allergy Asthma Immunol. 2002;88: 592
Change from
baseline
(mean, 95% CI)
mean baseline=2.0
* *
placebo, N=149
montelukast, N=155
loratadine, N=301
*p<0.01 vs placebo
Efficacy of a CysLT1 Receptor Antagonist
in Allergic Rhinitis with Seasonal Symptoms
61. Anti-Leukotriene Treatment in Allergic Rhinitis
Efficacy
• Equipotent to H1 receptor antagonists but with onset of
action after 2 days
• Reduce nasal and systemic eosinophilia
• May be used for simultaneous treatment of allergic
rhinitis and asthma
Safety
• Dyspepsia (approx. 2%)
63. Nasal Corticosteroids
reduction of
symptoms and exacerbations
reduction of
mucosal inflammation
reduction of
late phase reactions
priming
nasal hyperresponsiveness
1
reduction of
mucosal mast cells
reduction of
acute allergic reactions
2
• suppression of
glandular activity
and vascular leakage
• induction of
vasoconstriction
3
64. Onset of Action of Intranasal Budesonide Against
Allergen Exposure
(controlled environmental exposure - peak nasal inspiratory flow)
Day JH. et al. J Allergy Clin Immunol. 2000;105:489.
65. Mandl M. et al. Ann Allergy Asthma Immunol 1997;79:370
Comparative Efficacy of Nasal Corticosteroids
66.
67.
68.
69. Adapted from Di Lorenzo et al. Clin Exp Allergy 2004;934:259
0.5 0.8 1.1 1.4
fluticasone, N=20
fluticasone + cetirizine, N=20
fluticasone + montelukast, N=20
placebo, N=20
cetirizine + montelukast, N=20
Average congestion score over 6 weeks
[95% CI]
*
Various Treatment Combinations in
Seasonal Allergic Rhinitis
Nasal congestion score, Scale: 0-3
70. Adapted from Di Lorenzo et al. Clin Exp Allergy 2004;934:259
Average total symptom score over 6 weeks
[95% CI]
fluticasone, N=20
fluticasone + cetirizine, N=20
fluticasone + montelukast, N=20
cetirizine + montelukast, N=20
placebo, N=20
0 1 2 3 4 5
*
*
Various Treatment Combinations in
Seasonal Allergic Rhinitis
total symptom score
Scale: 0-12
71. Nasal Corticosteroids
• Most potent anti-inflammatory agents
• Effective in treatment of all nasal symptoms including
obstruction
• Superior to anti-histamines and anti-leukotienes
• First line pharmacotherapy for persistent allergic rhinitis
72. Nasal Corticosteroids
• Overall safe to use
• Adverse Effects
– Nasal irritation
– Epistaxis
– Septal perforation (extremely rare)
– HPA axis suppression (inconsistent and not clinically
significant)
– Suppressed growth (only in one study with
beclomethasone)
76. Subcutaneous Immunotherapy:
Effect on Serum Specific IgE
10
20
30
40
50
60
70
Anti - ragweed
IgE
(ng/ml)
Initiation of
immunotherapy
August
November
baseline year 1 year 2 year 6 year 7 year 8
Adapted from: Peng et al. J Allergy Clin Immunol 1992;89:519
77. Long-Term Efficacy of Subcutaneous Immunotherapy
Placebo Immunotherapy
80
60
40
20
May June July Aug.
Symptom
score
1989
Durham et al. N Eng J Med 1999;341:468
80 80
Immunotherapy continued
80
60
40
20
May June July Aug.
1993
60
40
20
May June July Aug.
Symptom
score
1994
60
40
20
May June July Aug.
1995
Immunotherapy discontinued
78. Dahl R et al., J Allergy Clin Immunol. 2006;118:434.
Sublingual Immunotherapy in
Grass Pollen-Induced Allergic Rhinitis
Treatment: grass allergen
tablets
SLIT, N=316
Placebo, N=318
80. Efficacy of Omalizumab in Seasonal Allergic Rhinitis
(ragweed pollen season)
Average
weekly
symptom
score
Placebo, N=136
Omalizumab
50mg, N=137
150mg, N=134
300mg. N=129
4 13 20 27 3
Aug
10 17 24 1
Sep Oct
8 15 22 29
1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
Casale T, et al. JAMA 2001;286:2956
• SQ treatments every 3-4 weeks x 3-4
• First dose prior to the pollen season
81. Omalizumab and Subcutaneous Immunotherapy in
Children: Study design
Week 0 Week 12 Week 36
SIT titration SIT maintenance + study drug
Prescreening
SIT (grass) + omalizumab
SIT (birch) + omalizumab
SIT (birch) + placebo
SIT (grass) + placebo
n = 55
n = 54
n = 59
n = 53
Randomization
Kuehr J et al. J Allergy Clin Immunol 2002;109:274
82. 0
1.0
Omalizumab
Placebo
+ birch SIT
Omalizumab
Placebo
+ grass SIT
0.8
0.6
0.4
0.2
n=55
n=54 n=59
n=53
p<0.001
Omalizumab and Subcutaneous Immunotherapy in
Children: Symptom Load
(rescue medications + symptom severity scores)
grass pollen season
0.26
0.61
0.89
0.49
p=0.03
p=0.001
Symptom
load
score
(median)
Kuehr J et al. J Allergy Clin Immunol 2002;109:274
83. Anti IgE - Omalizumab
• Not licensed to treat allergic rhinitis
• Could be considered in severe cases unresponsive to
conventional treatment
• Could be an adjunct to immunotherapy in severe cases